+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Controlled release of vancomycin from Poloxamer 407 gels

Controlled release of vancomycin from Poloxamer 407 gels

International Journal of Pharmaceutics (Amsterdam) 192(2): 183-193, Dec 10

The purpose of this study was to investigate Poloxamer 407 25% (w/w) formulations aimed at prolonging the residence time of vancomycin, a time-dependent antibiotic, in a body site with a high infectious risk. Reversible thermal gelation of the formulations permitted their local injection in liquid form and in situ gelation as they warmed to body temperature. Neither the rheological properties of the Poloxamer matrices nor the antibacterial activity of vancomycin was altered by their combination. In vitro, the dispersed form exhibited prolonged release, with a lower diffusion coefficient of vancomycin compared to the solubilized form (4.7 X 10-8 vs 2.1 X 10-7 cm2 s-1). In rats, a single dose was well tolerated and resulted in a high local concentration for 24 h (> 131 mg l-1 for the solubilized form), followed by lower but effective antibacterial levels for at least 8 days. Controlled-release profiles, good preservation of vancomycin activity, good tolerability in rats, and ease of administration suggest that Poloxamer 407 may be useful as a vancomycin delivery vehicle for local prophylaxis of infections, especially in prosthetic surgery.

(PDF emailed within 0-6 h: $19.90)

Accession: 010385414

Download citation: RISBibTeXText

PMID: 10567749

DOI: 10.1016/s0378-5173(99)00307-5

Related references

Controlled release of human growth hormone from poloxamer gels injected in rats. Pharmaceutical Research (New York) 13(9 SUPPL ): S88, 1996

Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. Journal Of Controlled Release. 49(1): 21-26, 1997

Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels. Journal Of Controlled Release. 52(1-2): 169-178, Ch 2, 1998

Sustained release of lidocaine from Poloxamer 407 gels. International Journal of Pharmaceutics 288(2): 235-244, 2004

Physicochemical and release studies of naproxen in poloxamer gels. International Journal Of Pharmaceutics (amsterdam). 129(1-2): 13-20, 1996

Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. International Journal of Pharmaceutics (Amsterdam) 167(1-2): 183-189, June 1, 1998

Sustained release of 5-FU from Poloxamer gels interpenetrated by crosslinking chitosan network. International Journal of Pharmaceutics 382(1-2): 39-44, 2010

Release rates of ketoprofen from poloxamer gels in a membraneless diffusion cell. Journal of Pharmaceutical Sciences 80(3): 280-283, 1991

Novel poloxamer pluronic and poloxamine tetronic hydro gels swelling and drug release. Journal of Pharmacy & Pharmacology 32(SUPPL): 5P, 1980

Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels. Journal of Pharmacy & Pharmaceutical Sciences 13(2): 286-302, 2010

Poloxamer-hydroxyethyl cellulose-α-cyclodextrin supramolecular gels for sustained release of griseofulvin. International Journal of Pharmaceutics 500(1-2): 11-19, 2016

Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems. European Journal of Pharmaceutics and Biopharmaceutics 89: 74-81, 2015

Controlled release of morphine from a poloxamer 407 gel. International Journal of Pharmaceutics 452(1-2): 266-269, 2014

Characterization of gelation process and drug release profile of thermosensitive liquid lecithin/poloxamer 407 based gels as carriers for percutaneous delivery of ibuprofen. International Journal of Pharmaceutics 490(1-2): 180-189, 2016